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Abstract
Dopamine signaling modulates voluntary movement and reward-driven behaviors by acting through G protein-coupled
receptors in striatal neurons, and defects in dopamine signaling underlie Parkinson’s disease and drug addiction. Despite
the importance of understanding how dopamine modifies the activity of striatal neurons to control basal ganglia output,
the molecular mechanisms that control dopamine signaling remain largely unclear. Dopamine signaling also controls
locomotion behavior in Caenorhabditis elegans. To better understand how dopamine acts in the brain we performed a large-
scale dsRNA interference screen in C. elegans for genes required for endogenous dopamine signaling and identified six
genes (eat-16, rsbp-1, unc-43, flp-1, grk-1, and cat-1) required for dopamine-mediated behavior. We then used a combination
of mutant analysis and cell-specific transgenic rescue experiments to investigate the functional interaction between the
proteins encoded by two of these genes, eat-16 and rsbp-1, within single cell types and to examine their role in the
modulation of dopamine receptor signaling. We found that EAT-16 and RSBP-1 act together to modulate dopamine
signaling and that while they are coexpressed with both D1-like and D2-like dopamine receptors, they do not modulate D2
receptor signaling. Instead, EAT-16 and RSBP-1 act together to selectively inhibit D1 dopamine receptor signaling in
cholinergic motor neurons to modulate locomotion behavior.
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Introduction
Dopamine (DA) modulates neural activity by acting through
two classes of G protein-coupled receptors. These receptors are
expressed in many regions of the brain including the prefrontal
cortex where they can affect short-term working memory and in
the basal ganglia where they affect motor and reward behaviors
[1–4]. Defects in DA signaling contribute to neurological disorders
that include schizophrenia and Parkinson’s disease.
There are five DA receptors in mammals and they are grouped
into the D1-like class (D1 and D5 receptors) and the D2-like class
(D2, D3, and D4 receptors) based on biochemistry, pharmacology,
and amino acid sequence similarity [5]. Biochemically, D1-like
receptors can enhance adenylyl cyclase (AC) activity by acting
through the G protein subunits Gas and/or Gaolf and D2-like
receptors either do not modulate AC or they inhibit its activity by
acting through Gai/o subunits [6–11]. Coupling of DA receptors
to specific G protein subunits however is not strict as each receptor
can act through several different a subunits depending on the cell
type in which the receptor is expressed and a subunit availability
[12–14].
Binding of DA to its receptor induces the coupled G protein a
subunit to exchange GDP for GTP, causing the separation of the a
subunit from the bc complex. Both freed a and bc subunits can
modulate the activity of downstream molecules. The best studied
of the a subunit targets is AC which, when activated, converts
ATP to cAMP to directly modulate the activity of protein kinase A
(PKA). PKA then phosphorylates a number of target molecules
including AMPA and NMDA receptors to affect their activity
and/or localization. The bc complex is also capable of acting on
downstream targets including phospholipase C (PLC) and ion
channels [15]. While DA receptors often couple to Gaso rG ai/o
to modulate AC activity, there is evidence that the D5 receptor
and the D1/D2 heterodimer can act through Gaq to activate
PLCb and generate IP3 and diacylglycerol (DAG) [16,17]. The
physiological targets of signaling downstream of D1-like receptors
and Gaq are currently only partly described but may include the
activation of calcium/calmodulin protein kinase II (CamKII) [18].
Signaling activated by DA receptors continues until the GTP
bound to the a subunit is hydrolyzed. To rapidly shut down G
protein receptor signaling the weak intrinsic GTPase activity of the
a subunit is enhanced by a family of regulators of G protein
signaling proteins (RGS proteins). RGS proteins bind the a
subunit and stabilize the transition state of hydrolysis speeding up
the rate of GTP hydrolysis more than 40-fold [19,20]. While RGS
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precisely how they are regulated.
DA also modulates neural activity to affect locomotion in C.
elegans. The mammalian enzymes involved in DA synthesis, vesicle
loading and reuptake by neurons all have C. elegans homologs, and
mutants for each of these homologs have previously been analyzed
[21,22]. DA is synthesized in just eight of the 302 neurons found in
C. elegans and these eight neurons appear to be mechanosensory
[23,24]. They release DA when the animal encounters a food
source such as bacteria [24]. DA released from these neurons
binds to D1-like (DOP-1) and D2-like (DOP-3) receptors (similar
in sequence to those found in the mammalian brain) expressed in
the motor neurons to modulate locomotion behavior. DA inhibits
locomotion behavior by acting through the DOP-3 receptor but
can also enhance locomotion by acting through the DOP-1
receptor [25]. We have shown previously that the DOP-3 receptor
couples to the G protein a subunit GOA ˜1 (80% identical to the
mammalian Gao) and the DOP-1 receptor couples to the a
subunit EGL-30 (80% identical to the mammalian Gaq) but few
other downstream targets have been identified [25].
Increased concentrations of synaptic DA, caused either by the
application of exogenous DA [25] or by mutations of the DA
transporter dat-1, [26], cause animals to become paralyzed.
Regardless of the source of DA, paralysis is caused, at least in
part, by hyperactivation of the DOP-3 receptor expressed in the
motor neurons [26,27]. To begin to better understand how DA
modulates neural activity in the brain we performed a large-scale
dsRNAi screen in C. elegans searching for genes that were required
for endogenous DA signaling. We identified six genes from this
screen that encode UNC-43 (the homolog of mammalian
calcium/calmodulin-dependent protein kinase CamKII), CAT-1
(homolog of the mammalian monoamine transporter VMAT2),
GRK-1 (homolog of mammalian G protein receptor kinase 4
family), FLP-1 (an FMRF-amide related peptide), EAT-16 (the
homolog of mammalian R7 RGS protein RGS9), and RSBP-1
(homolog of the mammalian R7 RGS binding protein R7BP).
Here we have characterized the function of EAT-16 and RSBP-1
and show that they are both necessary for endogenous DA
signaling. Using a combination of genetic and behavioral studies
that allowed us to examine the physiological roles of EAT-16 and
RSBP-1 in single cell types, we found that EAT-16 and RSBP-1
function together in cholinergic motor neurons to modulate D1-
like (DOP-1) receptor signaling in vivo.
Results
Large-scale dsRNA interference screen identifies genes
required for endogenous DA signaling
We performed a large-scale dsRNA interference (dsRNAi)
screen to identify new genes required for DA signaling. For this
screen we used dat-1 mutant animals. dat-1 encodes a DA
transporter similar to that found in mammals which is capable
of transporting excess DA from the synapse back into dopami-
nergic cells [28]. Mutations in dat-1 result in increased synaptic
DA levels and caused an abnormal locomotion behavior known as
swimming-induced paralysis or SWIP [26]. Wild-type animals
when placed in water swim continuously for more than 30 minutes
while dat-1 mutants become paralyzed within 6–10 minutes of
swimming [26]. The reduced rate of locomotion observed in dat-1
mutants is caused by excess DA acting through the D2-like DOP-3
receptor in motor neurons that innervate body muscle cells
[26,27]. We fed dat-1 mutant animals dsRNA targeted against C.
elegans genes and identified those genes whose expression was
required for dat-1 mutants to exhibit the SWIP behavior (thus a
SWIP suppressor screen). In this screen we expected to identify
genes that were either required for DA synthesis and release from
dopaminergic neurons or that were required for modulating DA
signaling in dopamine-receptive neurons. Because C. elegans
neurons are refractory to RNA-mediated interference, we
combined the dat-1 mutation with mutations in two genes that
enhance RNAi effects in neurons but that do not affect SWIP
behavior [29,30] to generate the strain XP292 (genotype: dat-1
(ok157); eri-1 (mg366); lin-15 (n744)).
In the screen we placed 30610 L1 stage XP292 larvae on agar
plates containing bacteria that expressed a single dsRNA and
allowed them to feed and reproduce for six days to generate first
generation (F1) broods of $500 animals. When the oldest F1
animals were L4 stage larvae we washed the entire population of
animals off the food plates and assayed them for SWIP behavior.
In initial trials with small populations of animals only 6%62% of
XP292 animals fed bacteria containing empty vector (pL4440)
were moving after 10 minutes while 44%62% of dop-3 fed animals
were capable of movement after this time period (Figure 1A). In
the screen we selected as positive ‘‘hits’’ any gene that suppressed
SWIP behavior such that .40% of animals were moving after
10 minutes.
We have so far surveyed 19% of all C. elegans genes (3,610 total
genes). Of these, dsRNAi of 681 genes (,19% of genes tested)
Figure 1. Quantitative analysis of SWIP behavior in knockdown
or null mutants of dopamine signaling genes. (A), SWIP behavior
of XP292 animals fed dsRNA-expressing bacteria. The dsRNA fed to
XP292 animals is indicated below each bar. XP292 animals fed bacteria
containing empty vector pL4440 become paralyzed within 10 min of
swimming while animals fed bacteria expressing dsRNA that targets
dop-3 continue to swim under these conditions. Students t test,
asterisks indicate p,0.001. (B), SWIP behavior of animals with null
mutations in genes identified in the dsRNAi screen. EAT-16, RSBP-1,
UNC-43, FLP-1, AND GRK-1 are required for SWIP behavior caused by
dat-1 mutation. Each measurement shown in either panel represents
the mean of five trials of 10 L4 animals each for a total of 50 animals per
dsRNA fed or mutant strain. Error bars represent standard error of the
mean. All strains were compared using one-way ANOVA with
Bonferroni’s post hoc test. Single asterisks indicate p,0.001. Double
asterisks indicate p,0.01. Except where indicated by the connecting
line, all statistical comparisons shown are to dat-1 single mutants. We
note that grk-1 single mutants showed significant SWIP when
compared to wild-type animals but that grk-1 also suppressed dat-1-
induced SWIP.
doi:10.1371/journal.pone.0037831.g001
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dsRNA-fed animals to sustain a brood. The three most common
terminal lethal phenotypes observed included: 1) larval arrest; 2)
failure of animals to produce eggs; and 3) the production of eggs
that failed to hatch. We also identified six genes required for the
SWIP phenotype (Table 1).
XP292 animals fed dsRNA targeting all six identified genes (eat-
16, rsbp-1, unc-43, flp-1, grk-1, and cat-1) resulted in .50%
suppression of the dat-1 SWIP phenotype during both the initial
screen and in subsequent retests. cat-1 encodes the monoamine
vesicle transporter and is required to load DA into synaptic vesicles
[31]. We expected to identify genes involved in the synthesis,
vesicle loading and release of DA and so the identification of cat-1
indicated that the screen could identify genes required for DA
signaling. We selected one mutant allele to represent each of the
five remaining genes, combined these null mutations with the dat-1
mutation, and tested the resulting double mutants for SWIP
behavior to confirm our screen results (Figure 1B). The swimming
behavior of eat-16, rsbp-1, unc-43, and flp-1 single mutants was
similar to each other and to wild-type animals while grk-1 showed
some defects in swimming. Regardless, we found that mutations in
each of the five genes identified in the dsRNA screen suppressed
the SWIP phenotype of dat-1 single mutant animals (dat-1 single
mutants 2%62% moving, eat-16; dat-1 double mutants 76%65%,
rsbp-1; dat-1 double mutants 90%64%, dat-1; unc-43 double
mutants 87%62%, dat-1; flp-1 double mutants 100%60%, dat-1;
grk-1 double mutants 28%62%) (Figure 1B). These results indicate
that RSBP-1, EAT-16, UNC-43, FLP-1, and GRK-1 are each
required for the SWIP behavior caused by excess endogenous DA
signaling in dat-1 mutants and suggest that these proteins mediate
endogenous DA signaling.
eat-16 encodes an R7 class RGS protein which acts as a GTPase
accelerating protein for Ga subunits and is similar to members of
the mammalian R7 RGS9 protein family [32]. rsbp-1 encodes an
R7 anchoring protein homologous to mammalian R7BP [33]. Our
previous analysis of DA signaling implicated EAT-16 as a
regulator of D1 (DOP-1) signaling [25] and, while no particular
signaling pathway was implicated, others have demonstrated that
EAT-16 and RSBP-1 act together to control aspects of locomotion
and egg-laying behavior in C. elegans [33]. The interaction between
EAT-16 and RSBP-1 is similar to that described for RGS9-2 and
R7BP in mammals [34] where it has been suggested that the
RGS9-2/R7BP complex regulates D2 receptor signaling [35].
Thus we decided to investigate whether RSBP-1 acts together with
EAT-16 to modulate DA signaling in C. elegans, and if so, whether
it regulates D1 (DOP-1) or D2 (DOP-3) signaling.
rsbp-1 mutants are defective in other DA-mediated
behaviors
RSBP-1 is the sole C. elegans homolog of the mammalian R7
RGS binding proteins R7BP and R9AP. In mammals R9AP is
expressed exclusively in the retina where it anchors the R7 RGS
protein RGS9-1 to photoreceptor outer segment disk membranes
to modulate Gat activity in response to light [36]. In contrast,
R7BP is widely expressed in the brain with higher expression levels
in richly dopamine-innervated regions including the striatum and
olfactory tubercle, where it is coexpressed and binds to the RGS7
and RGS9-2 proteins [37–39]. While R7BP can bind to both
RGS7 and RGS9-2 in brain extracts, most R7BP found in the
striatum is bound to RGS9-2 and this physical interaction is
required for the stability and function of the RGS9-2 protein [40].
The coexpression of R7BP, RGS7, and RGS9-2 in DA-receptive
regions of the brain led others to investigate whether these
molecules were able to modulate DA signaling [35,41–43]. The
results of these studies suggest that RGS9-2, RGS7, and R7BP can
all modulate locomotion behavior and an animal’s response to
addictive drugs, but the cellular and molecular mechanisms of
their action on DA signaling remain largely unclear.
To begin to investigate the role of RSBP-1 in DA signaling we
examined the behavioral response of rsbp-1 mutants to exogenous
DA (Figure 2A). Locomotion rate is modulated by DOP-1 and
DOP-3 receptors acting in cholinergic and GABAergic motor
neurons that innervate body wall muscle cells [25,27]. Exogenous
DA also acts through these receptors to have opposite effects on
locomotion: DOP-3 signaling inhibits locomotion and DOP-1
signaling enhances locomotion [25]. Wild-type animals exposed to
exogenous DA slow their locomotion rate until, at sufficiently high
DA concentrations, they are unable to move and appear
paralyzed, suggesting that DOP-3 signaling prevails over DOP-1
signaling in the presence of high concentrations of DA [25,44]
(Figure 2A). Consistent with this, dop-3 mutants are resistant to
exogenous dopamine and dop-1 mutants are hypersensitive to the
effects of exogenous DA on locomotion rate [25](Figure 2A). We
found that rsbp-1 mutants, like dop-3 mutants, were resistant to the
paralytic effects of exogenous dopamine suggesting that RSBP-1
mediates the effects of exogenous DA and thus may (like DOP-3)
mediate endogenous DA signaling (Figure 2A).
This result is contrary to what we would expect if RSBP-1 were
acting with an R7 RGS protein to inhibit the activity of DOP-3.
Indeed, we would expect rsbp-1 mutations to cause behavioral
defects opposite to those caused by mutations in the signaling
pathways that they inhibit. Therefore this result suggests that
RSBP-1 does not inhibit signaling by the D2-like DOP-3 receptor.
Notably, mutations in the D1-like DOP-1 receptor cause
behavioral defects that are opposite to those caused by mutations
in the DOP-3 receptor [25] and thus opposite to those caused by
mutations in RSBP-1 suggesting that RSBP-1 may inhibit D1-like
DOP-1 signaling.
To further support a role for RSBP-1 in DA signaling we tested
rsbp-1 mutants for defects in basal slowing response, a behavior
that is dependent on endogenous DA signaling [24]. Wild-type
animals slow their locomotion rate when they encounter a source
of food such as a bacterial lawn and this response, known as basal
slowing, requires DA signaling [24](Figure 2B). We found that
rsbp-1 mutants, like cat-2 mutants (cat-2 encodes tyrosine hydrox-
ylase, required for DA biosynthesis), and mutants in the DA
receptor dop-3 fail to slow in response to food (Figure 2B) (wild-type
animals show 45% slowing 62%, cat-2 mutants 1% slowing 65%,







grk-1 G protein receptor kinase GRK4-6
flp-1 FMRFamide related peptide none*
eat-16 R7 RGS protein RGS6, 7, 9, 11**
rsbp-1 R7 RGS binding protein R7BP
cat-1 monoamine vesicular transporter VMAT2
*FLP-1 encodes up to eight invertebrate-specific FMRFamide-related peptides.
**EAT-16 is similar in both sequence and domain structure to all four human R7
RGS protein family members but is not clearly more related to one member
than the others.
doi:10.1371/journal.pone.0037831.t001
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62%). As the ability of animals to slow in response to food is
absolutely dependent upon endogenous DA signaling, these results
indicate that RSBP-1 is required for dopamine signaling in vivo and
again suggest that RSBP-1 is not acting as an inhibitor of D2-like
DOP-3 receptor signaling as both rsbp-1 and dop-3 mutants fail to
slow in response to food. Like rsbp-1 mutants, eat-16 mutants also
fail to slow in response to food [25] suggesting that RSBP-1 and
EAT-16 act together to modulate endogenous DA signaling.
RSBP-1 is expressed in DA-receptive neurons that control
locomotion
In order for RSBP-1 to regulate DA signaling pathways (either
D1- or D2-like) it must be expressed in neurons that also express
the DA receptors. Thus we examined the expression pattern of
RSBP-1. The expression patterns of the DOP-1 and DOP-3
receptors have been already examined [25,45]. We generated
transgenes in which the promoter for rsbp-1 was used to direct the
expression of the green and red fluorescent proteins GFP and
mCherry, respectively (rsbp-1p::GFP and rsbp-1p::mCherry trans-
genes). These reporter transgenes were separately injected into
animals and transgenic progeny were inspected for fluorescence
(Figure 3). Similar to a previous analysis of rsbp-1 expression [33],
we found that the reporter transgene was expressed in head and
tail neurons and motor neurons of the ventral cord that innervate
body-wall muscle cells (Figure 3A). We also observed expression in
vulval, pharyngeal, and body-wall muscle cells (Figure 3A). We
previously showed that DA modulates locomotion behavior by
acting through the DOP-3 receptor, which is expressed in both
GABAergic and cholinergic motor neurons of the ventral cord and
by acting through the DOP-1 receptor, which is expressed in the
cholinergic motor neurons but not the GABAergic motor neurons
[25]. The rsbp-1p::GFP transgene was expressed in many ventral
cord motor neurons (Figure 3A). Only cholinergic and GABAergic
motor neuron cell bodies are found in the ventral cord of C. elegans.
There are 44 cholinergic motor neurons and 13 GABAergic motor
neurons located in the ventral cord between the retrovesicular
ganglia and pre-anal ganglia of C. elegans [46]. We consistently
found rsbp-1p::GFP expression in .45 ventral cord neurons
between these ganglia indicating that RSBP-1 was expressed in
both cholinergic and GABAergic motor neurons (Figure 3A). We
verified the expression of the rsbp-1p reporter transgenes in both
GABAergic and cholinergic motor neurons in two ways. First, we
generated rsbp-1p::GFP, unc-47p::mCherry double transgenic
animals and examined these animals for coexpression of GFP
and mCherry in ventral cord motor neurons. The unc-47p::
mCherry transgene is expressed only in GABAergic cells (unc-47
encodes the transporter required for loading GABA into synaptic
vesicles; [47]). We found that rsbp-1p::GFP was coexpressed in the
ventral cord neurons with this GABAergic-specific marker (data
not shown). Second, we generated rsbp-1p::mCherry, dop-1p::GFP
double transgenic animals and examined these animals for
coexpression of GFP and mCherry in ventral cord motor neurons.
dop-1p::GFP is expressed in the cholinergic, but not the
GABAergic neurons, of the ventral cord [25] and we found that
the rsbp-1p::mCherry reporter transgene was coexpressed with dop-
1p::GFP in the cholinergic ventral cord neurons (Figure 3B–E). In
these double transgenic animals dop-1p::GFP transgene is stably
integrated into the chromosome and therefore this transgene is
present in all cells of the animal and caused GFP expression in all
cholinergic motor neurons. In contrast, the rsbp-1p::mCherry
transgene is present as an extrachromosomal array. Extrachro-
mosomal arrays are not stable and can be lost as the result of
unequal partitioning of the array between daughter cells during
development resulting in a mosaic expression pattern of the
transgene. Thus the lack of mCherry expression in individual
motor neurons could be due to loss of the transgene and is not
necessarily an indication of a lack of rsbp-1 promoter activity.
However, since dop-1p::GFP is active in all cholinergic motor
neurons the neuron cell bodies in Figure 3E that express mCherry
but not GFP must be GABA neurons. The results presented here
indicate that RSBP-1 is expressed in GABAergic motor neurons
(with the DOP-3 receptor) and is also expressed in cholinergic
motor neurons (with both DOP-1 and DOP-3 receptors).
RSBP-1 functions in the cholinergic motor neurons to
mediate dopamine signaling
To help determine which DA receptor is modulated by RSBP-
1, we next determined where RSBP-1 functions to mediate
dopamine signaling. For this we used promoters whose activity is
restricted to specific cells of the animal to drive the expression of
RSBP-1 and tested the ability of such transgenes to rescue the DA
Figure 2. Analysis of dopamine signaling defects in rsbp-1
mutants. (A), Dose-response curves measuring locomotion behavior in
response to exogenous dopamine. Shown are the percentages of
animals moving 20 min after being placed on agar plates containing
the indicated concentrations of dopamine. Each data point represents
the mean 6 standard error of the mean for three trials totaling at least
75 animals. (Two way ANOVA with Bonferroni post hoc test, *p,0.0001,
1p,0.01,
{p,0.05 when compared to the wildtype). (B), Quantitative
analysis of basal slowing behavior. For each strain, locomotion rates in
the absence of bacteria (white bars) and presence of bacteria (black
bars) were calculated as the average of 30 observations. Error margins
shown indicate 95% confidence intervals. Asterisks indicate values
significantly different from the 45% slowing seen in the wildtype. (One-
way ANOVA with Bonferroni post hoc test, asterisks indicate p,0.001).
The percent slowing in the presence of bacteria for each strain is shown
at the right. rsbp-1 mutants are defective in endogenous dopamine
signaling.
doi:10.1371/journal.pone.0037831.g002
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40mM DA (Figure 4). At 40mM DA, rsbp-1 mutants were resistant
to paralysis (68%62% moving animals) while wild-type animals
were completely paralyzed (0%60% moving animals). We first
expressed RSBP-1 from its own promoter and found that this
transgene was capable of complete rescue of DA response
(Figure 4). rsbp-1 null animals carrying a transgene that expressed
RSBP-1 coding sequence from its native promoter (transgene
designation: rsbp-1p::RSBP-1) showed DA sensitivity similar to
wild-type animals (2%61% animals moving) while transgenic
animals that carried a transgene that included the rsbp-1 promoter
but which lacked any rsbp-1 coding sequence (transgene designa-
tion: rsbp-1p::EMPTY) showed no rescue (69%61% moving).
Because RSBP-1 was expressed in both neurons and muscle cells
(Figure 3) and both cell types are required for locomotion
behavior, we next expressed RSBP-1 from the muscle-specific
promoter myo-3p, which is active in all body-wall muscle cells [48].
This transgene (myo-3p::RSBP-1) showed some rescue of DA
sensitivity (29%62% animals moving) compared with transgenic
animals that expressed the control transgene myo-3p::EMPTY
(60%63% animals moving) suggesting that RSBP-1 can function
in muscle cells to affect DA response. Next we expressed RSBP-1
from the unc-119 promoter, which is active in all neurons but is not
active in muscle cells [49]. This transgene, (unc-119p::RSBP-1),
strongly rescued the rsbp-1 mutant defect such that only 3%61%
of the transgenic animals were able to move compared to
67%63% for animals that expressed the control transgene (unc-
119p::EMPTY). Thus, RSBP-1 functions in both neurons and
muscle cells to affect locomotion but its primary site of function in
DA signaling is in neurons. Because the DOP-1 and DOP-3
receptors are differentially expressed in the cholinergic and
GABAergic motor neurons we wanted to test whether rsbp-1
expression in the cholinergic or the GABAergic ventral cord motor
neurons was sufficient to rescue the rsbp-1 DA signaling defect. For
this we used the unc-17 and unc-47 promoters, which are active in
the cholinergic and GABAergic motor neurons, respectively
[47,50]. Expression of an unc-17p::RSBP-1 transgene in the
cholinergic motor neurons was sufficient to rescue the DA
sensitivity of rsbp-1 mutants (11%61% animals moving), com-
pared to 74%63% for animals that expressed the unc-17p::EMP-
TY transgene. Finally, we found that expression of RSBP-1 in the
GABAergic cells using the unc-47p::RSBP-1 transgene failed to
rescue the DA sensitivity of rsbp-1 mutants (68%62% animals
moving) compared to animals that expressed the control transgene
unc-47p::EMPTY (63%65% animals moving). These data clearly
indicate that RSBP-1 functions in the cholinergic and not the
GABAergic motor neurons to mediate DA signaling.
The DOP-1 and DOP-3 receptors control locomotion rate in
response to exogenous DA, and of these two receptors, DOP-3 is
the only receptor expressed in the GABA motor neurons.
Therefore our data strongly suggest that RSBP-1 does not
modulate D2-like DOP-3 receptor signaling; at least not in GABA
motor neurons.
RSBP-1 acts with the R7 RGS protein EAT-16 and not with
EGL-10 to modulate DA signaling
In mammals the R7BP protein can interact with all four R7
RGS proteins in brain extracts [39]. While this suggests that
R7BP-RGS protein complexes are important for modulating G
protein receptor signaling in the brain, the physiological signifi-
cance of these interactions is not yet clear. Since there are two R7
RGS proteins in C. elegans (EAT-16 and EGL-10) we sought to
determine whether they both acted with RSBP-1 to mediate DA
signaling. Thus we tested null mutations in eat-16 and egl-10 for
defects in DA-specific behaviors and compared them directly to
the behavioral defects observed in rsbp-1 mutants (Figure 5). First
we tested animals for defects in SWIP, a behavior controlled by
endogenous DA signaling. As shown earlier in Figure 1B, mutation
in eat-16, like the mutation in rsbp-1, suppressed the SWIP
phenotype of dat-1 mutants (Figure 5A). In stark contrast however,
we found that egl-10 mutants failed to suppress the SWIP
phenotype of dat-1 mutants as no dat-1; egl-10 double mutant
animals were moving after 10 minutes of swimming (Figure 5A).
That rsbp-1 and egl-10 mutations had opposite effects on SWIP
behavior suggests that RSBP-1 and EGL-10 do not act together to
modulate endogenous DA signaling. We note that mutation of egl-
Figure 3. Fluorescence of animals expressing rsbp-1 and dop-1
promoter transgenes. (A), young adult transgenic animal showing
expression of rsbp-1p::GFP in neurons of the head and retrovesicular
ganglia (left bracket), pre-anal ganglia and tail neurons (right bracket),
and vulval muscle cells (large arrows). Expression is also seen in the cell
bodies and processes of ventral cord motor neurons. (small arrows
indicate positions of the ventral cord neuron cell bodies). Faint green
fluorescence can also be seen in body-wall and pharyngeal muscle cells.
(B–D), high-power magnification images of the ventral cord area of a
double transgenic animal expressing rsbp-1p::mCherry and dop-1p::GFP
transgenes. In all images dorsal is up and anterior is left. (B), Nomarski
image of double transgenic animal shown in panels C–E. (C), red
fluorescence of the mCherry protein expressed from the extrachromo-
somal transgene rsbp-1p::mCherry. (D), green fluorescence of GFP
protein expressed from the chromosomally integrated transgene dop-
1p::GFP. (E), merged image showing coexpression of rspb-1 and dop-1
transgenes in cholinergic motor neurons. Asterisks indicate the
positions of cell bodies of GABAergic motor neurons that express
rsbp-1p::mCherry but not dop-1p::GFP. RSBP is expressed in both
cholinergic and GABAergic motor neurons of the ventral cord and is
thus coexpressed with both DOP-1 and DOP-3 receptors. Some cells of
the ventral cord shown in panel E express the dop-1p::GFP but not the
rsbp-1p::mCherry transgene. The relative position of these non-
mCherry-expressing cells varies among transgenic animals suggesting
that the lack of expression of the rsbp-1p::mCherry transgene in some
cells that express the dop-1p::GFP transgene is due to random loss of
the extrachromosomal transgene during cell division and not due to
restricted expression of rsbp-1.
doi:10.1371/journal.pone.0037831.g003
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part, by unregulated DOP-3 activity, consistent with previous
reports indicating that: 1) EGL-10 inhibits DOP-3 signaling [25];
and 2) SWIP is caused by excess DA signaling through DOP-3
[26,27].
To examine the functional interaction between RSBP-1 and the
two R7 RGS proteins more directly we tested rsbp-1 eat-16; dat-1
and rsbp-1; dat-1; egl-10 triple mutants for SWIP (Figure 5A). We
found no significant difference in SWIP behavior of rsbp-1 eat-16;
dat-1 triple mutants compared to either rsbp-1; dat-1 double
mutants or eat-16; dat-1 double mutants, consistent with rsbp-1 and
eat-16 acting together to modulate DA signaling. In contrast, rsbp-
1; dat-1; egl-10 triple mutants exhibited a SWIP phenotype that
was significantly different from that of rsbp-1; dat-1 double mutants
and was intermediate between that observed for dat-1 single and
rsbp-1; dat-1 double mutants indicating that rsbp-1 and egl-10
mutations have opposite effects on dat-1-induced SWIP. Thus,
using SWIP behavior as a measure of protein function, it appears
that RSBP-1 acts with EAT-16 and not with EGL-10 to modulate
endogenous DA signaling.
We then tested eat-16 and egl-10 mutants for defects in response
to exogenous dopamine. Again, like rsbp-1 mutants, eat-16 mutants
were resistant to exogenous DA while egl-10 mutants showed the
opposite effect and were more sensitive to exogenous dopamine
than wild-type animals (Figure 5B, top panel). Again, the opposite
effects of rsbp-1 and egl-10 mutations indicate that RSBP-1 and
EGL-10 do not act together to modulate DA signaling.
Because mutations in rsbp-1 and eat-16 caused similar behavioral
defects, we wanted to test whether RSBP-1 and EAT-16 always
functioned together to mediate DA signaling. Porter and Koelle
[33] previously showed that EAT-16 protein levels are reduced
(but importantly were not eliminated) in rsbp-1 null mutants, but
they did not examine RSBP-1 protein levels in eat-16 null mutants.
To determine whether RSBP-1 or the residual EAT-16 present in
rsbp-1 mutants was able to modulate DA signaling, we examined
the response of rsbp-1 eat-16 and rsbp-1; egl-10 double mutants to
exogenous DA (Figure 5B, two lower panels). We found that rsbp-1
eat-16 double mutants behaved in a manner that was indistin-
guishable from either rsbp-1 or eat-16 single mutants (Figure 5B,
middle panel) suggesting that the two proteins only act together to
modulate DA signaling. These data also suggest that the residual
EAT-16 present in rsbp-1 null mutant animals does not modulate
DA signaling and may be inactive. In contrast, we found that rsbp-
1; egl-10 double mutants showed a sensitivity to DA that was
similar to wild-type animals, clearly showing that EGL-10 and
RSBP-1 do not act together to modulate DA signaling (Figure 5B,
bottom panel). Finally, we tested eat-16; egl-10 double mutants and
found that they showed a sensitivity to exogenous DA that was
indistinguishable from rsbp-1; egl-10 double mutants (Figure 5B,
bottom panel). All together, our data indicates that RSBP-1 acts
with EAT-16 and not with EGL-10 to modulate DA signaling in
C. elegans.
RSBP-1 and EAT-16 act downstream of the D1/DOP-1
receptor
In our previous analysis of DA signaling, we provided evidence
suggesting that the R7 RGS protein EGL-10 inhibits DOP-3
signaling and that EAT-16 inhibits DOP-1 signaling [25]. In the
present work, our data thus far suggest that: 1) RSBP-1 does not
modulate D2-like DOP-3 signaling but rather might modulate D1-
like DOP-1 signaling; and 2) RSBP-1 acts with EAT-16 and not
EGL-10 to modulate DA signaling. Therefore, we next wanted to
test more directly whether RSBP-1 acted downstream of the DOP-
1 or the DOP-3 receptor.
Since R7BP and R7 RGS proteins act together to inhibit
receptor signaling in mammals (by accelerating the GTPase
activity of Ga subunits), we predicted that mutations in R7BP
would have opposite effects on behavior compared to mutations in
the receptor whose signaling it normally inhibits. We have shown
that both rsbp-1 and dop-3 mutants show similar defects in three
separate DA-specific behaviors. Mutations in both genes cause
resistance to exogenous DA (Figure 2A), suppress the locomotion
defects of dat-1 mutants (Figure 1), and cause similar defects in an
animal’s ability to slow in response to food (Figure 2B). These
results indicate that RSBP-1 does not inhibit DOP-3 signaling.
However, the data is also consistent with RSBP-1 and DOP-3
acting together to mediate DA signaling with RSBP-1 being
required for DOP-3 function. If RSBP-1 is required for DOP-3
signaling, dop-3 and rsbp-1 mutants would be expected to show
similar resistance to exogenous DA and rsbp-1; dop-3 double
mutants would be no more resistant to exogenous DA than either
dop-3 or rsbp-1 single mutants. We found however, that rsbp-1; dop-
Figure 4. Rescue of rsbp-1 function by transgenic expression
using cell-specific promoters. Animals were tested for paralysis as in
Figure 2A, except that a single concentration of DA was used (40 mM).
For control, non-transgenic animals (white bars), each measurement
shown represents the mean and 95% confidence interval of the mean
for at least 75 animals. Gray and black bars represent measurements
from rsbp-1 mutants carrying transgenes. The promoters used for
transgene expression are indicated at the bottom. Gray bars represent
measurements form control strains carrying empty vector transgenes,
which have promoters but no RSBP-1 sequences. We observed no
significant differences in the response of these transgenic animals when
compared to each other or to rsbp-1 null mutants that lacked
transgenes (p,0.001). Black bars represent measurements from strains
carrying transgenes from which the promoters express RSBP-1. For each
transgene, measurements of at least 75 animals for each of two or three
lines were averaged, and the means and 95% confidence intervals are
shown. Asterisks indicate that RSBP-1 expression gave significant rescue
compared to control animals that contained promoter but not RSBP-1
coding sequence. Asterisk indicates p,0.001. The intermediate
response of myo-3p::RSBP-1 animals was different from both unc-
47p::RSBP-1 animals (p,0.001) and from all other rescue strains
(p,0.001). All comparisons done using one-way ANOVA with Bonfer-
roni post hoc test. The unc-17 promoter gave nearly complete rescue of
rsbp-1 while the unc-47 promoter had no significant effect (p=0.32,
student’s t test) on behavior indicating that RSBP-1 acts in the
cholinergic motor neurons and not the GABAergic neurons to mediate
DA signaling.
doi:10.1371/journal.pone.0037831.g004
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DA than either dop-3 or rsbp-1 single mutants (dop-3 single mutants
18% moving 61%; rsbp-1 single mutants 39%66%; rsbp-1; dop-3
double mutants 69% moving 67%) (Figure 6A). Hence our data
indicate that RSBP-1 is not required for DOP-3 signaling.
Since resistance to exogenous dopamine can be caused by either
decreased DOP-3 signaling or increased DOP-1 signaling [25,27],
the DA resistance of rsbp-1 mutants could be due to increased
DOP-1 signaling. If RSBP-1 inhibits DOP-1 signaling we would
expect rsbp-1 and dop-1 mutants to have opposite effects on DA
sensitivity. Furthermore, if the DA resistance of rsbp-1 mutants was
due to increased DOP-1 signaling, we would expect that the DA
resistance of rsbp-1 mutants would be attenuated in rsbp-1; dop-1
double mutant animals. Indeed, this is exactly what we observed.
Unlike rsbp-1 mutants, dop-1 mutants are completely paralyzed by
a 20 minute exposure to 60 mM exogenous DA (Figure 6B). At
earlier time points and at lower concentrations of DA, we found
that dop-1 mutants were indeed more sensitive to exogenous DA
than wild-type animals and thus the effect of the dop-1 mutation is
opposite that of the rsbp-1 mutation (data not shown). Finally, we
found that the DA resistance of rsbp-1 mutants was attenuated
when the DOP-1 receptor was removed. Whereas 39%66% of
rsbp-1 mutants were resistant to 60 mM DA only 19%61% of
rsbp-1; dop-1 double mutants were resistant.
All together, our results indicate that RSBP-1 acts selectively
with the R7 RGS protein EAT-16 (and not the other R7 RGS
protein; EGL-10) to modulate DA signaling. Further, we have
shown that while EAT-16 and RSBP-1 are expressed together
with both D1- and D2-like receptors (DOP-1 and DOP-3) in
cholinergic cells they are able to selectively inhibit DOP-1
signaling in these cells.
Discussion
dsRNAi screen identified six genes required for DA
signaling
In this study we performed a large-scale RNAi screen to identify
genes that mediate endogenous DA signaling in C. elegans. This
screen resulted in the identification of six genes, unc-43, flp-1, grk-1,
cat-1, eat-16, and rsbp-1 that were required for the execution of DA-
mediated behaviors. unc-43 encodes the homolog of calcium/
calmodulin-dependent protein kinase (CamKII). Mammalian
CamKII has been previously implicated in signaling by both
D1-like [18,51] and D2-like receptors [52] and thus could also
play a role in DA signaling in C. elegans. flp-1 encodes a family of
eight FMRFamide-related invertebrate-specific peptides and may
Figure 5. Quantitative behavioral analysis of wild-type and
rsbp-1, eat-16, and egl-10 mutant animals. (A), SWIP behavior of
wild-type or mutant animals. Each measurement shown represents the
mean of five trials of 10 L4 animals each for a total of 50 animals per
strain. Error bars represent 95% confidence intervals. All strains were
compared using one-way ANOVA with Bonferroni post hoc test. Only
dat-1 and egl-10 single mutants, dat-1; egl-10 double mutants, and rsbp-
1; dat-1; egl-10 triple mutants were statistically different from the
wildtype (p,0.001). (B), Dose-response curves measuring paralysis
induced by exogenous dopamine. Shown are the percentages of
animals moving 20 min after being placed on agar plates containing
the indicated concentrations of dopamine. Each data point represents
the mean 6 standard error of the mean (s.e.m.) for three trials totaling
at least 75 animals. The responses of eat-1 and rsbp-1 mutants are not
statistically different from each other at any concentration of dopamine.
The response of egl-10 mutants is significantly different from the wild-
type at the indicated concentrations of dopamine (Two way ANOVA
with Bonferroni post hoc test, *p,0.0001,
1p,0.01).
doi:10.1371/journal.pone.0037831.g005
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identification of FLP-1 in our screen suggests that neuropeptide
and DA signaling may act together to modulate locomotion
behavior in C. elegans. grk-1 encodes the worm homolog of the
GRK4 family of G protein receptor kinases which include GRK4,
5, and 6. Members of this GRK family can regulate the activity of
the D1 and D2 receptors [54,55] and GRK6 knockout mice are
hypersensitive to the stimulatory effects of cocaine and amphet-
amine likely through enhanced D2 receptor signaling [56],
suggesting that D2 receptors may be a physiological target for
phosphorylation by GRK6. It has not yet been determined
whether C. elegans DA receptors are also regulated by GRKs, and
future characterization of grk-1 mutants may shed light on this
process. Finally, we identified cat-1 in our screen. cat-1 encodes the
monoamine vesicle transporter required to load dopamine and
serotonin into synaptic vesicles [31]. The identification of CAT-1
in the screen validated our approach in two ways. First it indicated
that the dsRNAi feeding approach was capable of knocking down
gene expression in neurons, and second, it demonstrated that the
screen could identify genes required for endogenous DA signaling.
In addition to these genes we also identified eat-16 and rsbp-1 in
our screen and showed that they are required to modulate DOP-1
receptor signaling. EAT-16 is one of two R7 RGS proteins found
in C. elegans, similar in both amino acid sequence and domain
structure to the mammalian R7 RGS proteins RGS6, 7, 9, and 11,
and RSBP-1 is homologous to the R7BP protein that is required
for the stability and function of RGS9-2. Mutations in eat-16 and
rsbp-1 cause similar DA-specific behavioral defects suggesting that
these two proteins function together to mediate DA signaling in C.
elegans.
Dopamine signaling mechanisms appear to be
conserved between mammals and C. elegans
We have now conducted two separate genetic screens to identify
molecules that either mediate the response of animals to
exogenous DA [25] or that modulate a DA-dependent locomotion
behavior (this study). From these screens we have identified 14
proteins required for DA signaling in C. elegans. Of these, 13 of
them (all except FLP-1) are homologous to mammalian proteins
expressed in the brain and have been linked to DA signaling in
mammals.
The similarities in DA signaling between C. elegans and
mammals are evident both at the amino acid and the functional
levels. For example, like in mammals, dopamine acts through D1-
(DOP-1) and D2-like (DOP-3) receptors in C. elegans and these
receptors are coupled to Gaq and Gao subunits, [11,16,25,57]. In
C. elegans dopamine signaling is modulated by R7 RGS proteins
that act as GAPs for these G protein subunits and there is building
evidence that D2 receptor and Gai/o signaling in the brain and in
cell lines is modulated by R7 RGS proteins [41–43,58,59]. While
no direct evidence yet indicates that D1 signaling may be
modulated by R7 RGS proteins there is substantial evidence that
Gaq signaling can be regulated by both RGS7 and RGS9 in
mammalian cells [60–62]. Finally, DOP-1 and DOP-3 receptors
act antagonistically in C. elegans to modulate acetylcholine release
from motor neurons [27] and D1 and D2 receptors in mammals
also have opposite effects on the release of both acetylcholine and
GABA in the brain [63,64].
In this study we have identified four new DA signaling genes,
three of which are conserved in mammals (grk-1, unc-43, and rsbp-
1). As mentioned earlier, GRK4–6 (homologs of GRK-1) and
CamKII (homolog of UNC-43) have previously been implicated in
DA signaling extending the similarity of DA signaling between the
two species. While a role for R7BP (homolog of RSBP-1) in DA
signaling has been recently described [35], it appears to act to
inhibit D2-like signaling. This is not consistent with the role we
have identified for RSBP-1 in C. elegans and suggests that perhaps
this mechanism of signaling may not be conserved (see below).
RSBP-1 and EAT-16 modulate DOP-1 (D1) receptor
signaling in vivo
We have demonstrated that RSBP-1 acts with EAT-16 to
inhibit signaling by the D1-like receptor DOP-1 and they do not
modulate the activity of the D2-like receptor DOP-3. Several lines
of evidence support this conclusion. First, mutations in rsbp-1, eat-
16, and dop-3 all blocked the ability of DA to inhibit swimming
behavior (Figure 1) [26,27]. Because RGS proteins act to inhibit G
protein-coupled receptor signaling, it is predicted that mutations in
eat-16 and rsbp-1 should cause behavioral effects opposite those
caused by mutations in the receptor whose signaling they regulate.
Figure 6. Quantitative analysis of dopamine response in rsbp-1;
dop-3 and rsbp-1; dop-1 double mutants. Shown are the
percentages of animals moving 20 min after being placed on agar
plates containing 60 mM dopamine. Each data point represents the
mean 6 standard error of the mean (s.e.m.) for three trials totaling at
least 75 animals. One-way ANOVA with Bonferroni post hoc test was
used to compare all strains. Single asterisk indicates p,0.001, double
asterisk indicates p,0.05. RSBP-1 acts with the R7 RGS protein EAT-16
to modulate signaling by the D1/DOP-1 receptor.
doi:10.1371/journal.pone.0037831.g006
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basal slowing, a second locomotory behavior controlled by
endogenous DA signaling (Figure 2B and [25]). This also indicated
that RSBP-1 and EAT-16 do not modulate DOP-3 signaling. In
previous studies we showed that DOP-1 signaling had effects on
these locomotion behaviors that were opposite to DOP-3 and thus
the behavioral effects that we observe for eat-16 and rsbp-1 mutants
are consistent with them acting as negative regulators of DOP-1
signaling. Third, while DOP-3 is expressed and functions in both
GABAergic and cholinergic neurons to modulate locomotion
behavior and response to DA, we found no function for RSBP-1 in
the control of DA response in GABA cells (Figure 4). Thus, RSBP-
1 likely does not modulate DOP-3 (D2) signaling in GABA motor
neurons. We did observe a function for RSBP-1 when we
expressed it in the cholinergic motor neurons where both DOP-1
and DOP-3 are expressed. This again suggested to us that RSBP-1
and EAT-16 might inhibit DOP-1 signaling instead of DOP-3
signaling.
We reasoned that the receptor signaling pathway normally
inhibited by RSBP-1 and EAT-16 would be more active in rsbp-1
and eat-16 mutants and that this increased receptor signaling is
what caused the altered response of rsbp-1 and eat-16 mutants to
exogenous DA (Figure 2). To identify that receptor we combined
mutations in eat-16 and rsbp-1 with mutations in dop-1 and dop-3
and found that the sensitivity of rsbp-1 and eat-16 mutants to DA
was restored only when the DOP-1 receptor was removed
demonstrating that the DOP-1 receptor is normally inhibited by
EAT-16 and RSBP-1 (Figure 6). In contrast, the ability of rsbp-1
and eat-16 mutants to move in the presence of exogenous DA was
increased further when the DOP-3 receptor was removed
(Figure 6). Together, these data clearly demonstrate that EAT-
16 and RSBP-1 act together to regulate DOP-1 and not DOP-3
signaling.
While we believe the mechanisms of DA signaling are conserved
between C. elegans and mammals, these last results conflict with
those from studies of RGS9-2 and R7BP function which suggest
that these proteins modulate signaling by D2 receptors and not D1
receptors. [41–43]. For example, RGS9-2 colocalizes with D2
receptors and not D1 receptors in CHO cells [43]. Rats in which
RGS9-2 was overexpressed unilaterally in the nucleus accumbens
exhibited a turning behavior indicative of an imbalance in DA
signaling when treated with a D2-selective agonist but not a D1-
selective agonist [41]. Finally, the RGS domain of RGS9-2
blunted the effects of D2-selective agonists on calcium channel
currents in dissociated striatal interneurons [42].
How can these apparently disparate results be reconciled? First,
it is possible that R7 RGS proteins and R7BP target different G
protein a subunits (and thus different receptors) depending upon
the cell type in which they are expressed or perhaps even where in
the cell they are found. For example, in addition to its apparent
ability to inhibit D2 signaling, mammalian RGS9-2 can also
inhibit NMDA and m-opioid receptors in behaving animals and in
biochemical assays in striatal extracts [65–67]. RGS9-2 can also
modulate M2 muscarininic receptor activity when expressed in
oocytes and in transfected CHO cells [68,69]. In a similar way, we
suspect that RSBP-1 and EAT-16 modulate signaling from other
G protein-coupled receptors in addition to DOP-1 in C. elegans. For
example, while EAT-16 and RSBP-1 are expressed in most or all
neurons (Figure 3, [32,33]) DOP-1 shows a more limited
expression pattern [25]. Furthermore, RSBP-1 is expressed in
both cholinergic and GABA motor neurons but DOP-1 is not
expressed in GABA neurons. We also found functional evidence to
suggest that RSBP-1 and EAT-16 regulate other G protein-
coupled receptors. The DA resistance of rsbp-1 and eat-16 mutants
can not be accounted for by unregulated activity of DOP-1 alone
as rsbp-1; dop-1 and eat-16; dop-1 double mutants are still resistant
to exogenous DA while dop-1 single mutants are not (Figure 6).
Thus it is possible that RGS9-2 (EAT-16) / R7BP (RSBP-1)
complexes can modulate signaling by many receptors including
both D1 and D2-like DA receptors. In further support of this,
mammalian RGS9-2 is expressed in most or all neurons of the
striatum including D2-expressing cells, D1- expressing cells, and
cholinergic interneurons [41,42].
The discrepancy might also be explained by our ability to
examine the function of these signaling proteins in vivo in single cell
types. In this work we directed the expression of transgenes using
well-defined promoters that are active in very select cell types
within the nervous system. Expressing these cell-specific transgenes
in null mutant animals allowed us to test protein function and the
interaction between two or more signaling proteins in single cell
types in live, behaving animals. Mammalian promoters are more
complex than those found in C. elegans and the number of well-
characterized mammalian promoters is small. In their study of
RGS9-2 function, Rahman et al. [41] drove expression of RGS9-2
in the striatum using viral-mediated overexpression techniques
that do not permit cell-type selectivity but instead cause expression
in most or all cells near the site of virus injection. As the striatum
consists of a heterogeneous population of cell types, this approach
will cause the increased expression of RGS9-2 in multiple cell
types. Because RGS9-2 likely acts at many different types of G
protein-coupled receptors, changes in its expression which are not
restricted in the cell-type affected can have confounding effects on
the activities of many receptors, cells, and circuits that ultimately
control a behavior. It is possible, therefore, that such overexpres-
sion strategies could cause complex signaling effects that confound
experimental results and obscure the true function (or site of
action) of the gene under investigation. Whether or not RGS9-2
and R7BP act together to modulate D1 receptor signaling in the
brain might be tested by using the D1 receptor promoter to drive
the expression of these proteins (or RNAi against them) only in D1
receptor expressing neurons [70].
Materials and Methods
Nematode Culture
Worm strains were maintained at 20uC under standard
conditions and double and triple mutants were generated using
standard genetic methods [71]. The wild-type strain used was
Bristol N2. Strains analyzed in this study were: LX1270: rsbp-
1(vs163) I, DA702: eat-16(ad702) I, XP139: dat-1(ok157) III (4x
outcrossed), NM1378: unc-43(js125) IV, XP461: flp-1(ok2811) IV
(4x outcrossed), VC10127: grk-1(gk1192) (not outcrossed),
MT8504: egl-10(md176) V, LX645: dop-1(vs100) X, and LX703:
dop-3(vs106) X. CB1112: cat-2 (e1112) III, XP154: eat-16(ad702);
dat-1(ok157), XP453: rsbp-1(vs163); dat-1(ok157), XP405: dat-
1(ok157); unc-43(js125), XP464: dat-1(ok157); flp-1(ok2811),
XP465: dat-1(ok157); grk-1(gk1192), XP390: dat-1(ok157); egl-
10(md176), XP391: rsbp-1(vs163); egl-10(md176), XP349: eat-
16(ad702) rsbp-1(vs163), XP392: rsbp-1(vs163); dop-3(vs106),
XP389: eat-16(ad702); dop-3(vs106), XP357: rsbp-1(vs163); dop-
1(vs100), XP388: eat-16(ad702), dop-1(vs100), LX1313: eat-
16(ad702); egl-10(md176), XP462: eat-16(ad702) rsbp-1(vs163); dat-
1(ok157), XP463: rsbp-1(vs163), dat-1(ok157); egl-10(md176). The
RNAi screen was conducted using XP292: dat-1(ok157); eri-
1(mg366); lin-15b(n744).
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The triple mutant strain XP292 was used for the dat-1 SWIP
suppressor screen. A C. elegans feeding dsRNA library was
purchased from Open Biosystems. The efficacy of dsRNA
knockdown was strictly dependent on maintenance of dsRNA
plasmid in the bacteria used to feed animals. We found that
plasmid was lost at high frequency from bacteria grown in
ampicillin up to 2 mg/ml. We therefore did not use this antibiotic
to grow bacteria. Bacteria grown in liquid media were less prone
to plasmid loss than bacteria grown on solid agar surfaces and we
found that liquid cultures containing 500 mg/ml carbenicillin was
sufficient to ensure 100%615% plasmid retention, while 2 mg/ml
carbenicillin was needed to ensure plasmid retention when
bacteria were grown on agar plates.
The 96-well plates containing dsRNA-expressing bacterial
clones were thawed and replica-plated into 150 ml LB medium
containing 8% glycerol, 16 mg/ml tetracycline, 3.2 mg/ml
carbenicillin using a 96-pin Boekel replicator and were grown
for 8–10 hr at 37uC with shaking (450 RPM, orbit 3 mm) to
generate duplicate library plates. This unusually high concentra-
tion of carbenicillin was necessary as ,50% of the bacteria in each
culture from the original library plates did not contain plasmid.
Bacteria from duplicate library plates were transferred using a 96-
pin replicator to agar-filled omniplates containing LB media with
16mg/ml tetracycline and 2 mg/ml carbenicillin. The bacteria on
these omniplates were grown at 37uC for 15–18 hr and were then
stored inverted at 4uC for up to one week. Bacteria from these
omniplates served as the source of food for the screen. Library
bacterial clones were replicated from omniplates into deep well
(2 ml) 96-well dishes each well containing 1 ml LB media with
16 mg/ml tetracycline and 500 mg/ml carbenicillin. These deep
well dishes were shaken flat for 24 hr at 37uC at 650 RPM (orbit
3 mm) until the cultures were saturated. After shaking, 150mlo f
each culture was transferred to the surface of NGM agar media
containing 2 mg/ml carbenicillin, 1mM IPTG but without
tetracycline in 12 well plates and the bacteria were allowed to
absorb into the agar for 24 hr at room temperature. The next day,
30610 synchronized L1 XP292 animals were placed in each well
of the 12-well NGM plates and stored at 20uC for 5–6 days in a
humidified chamber. For each 96-well library plate tested we
included one test well that contained bacteria with empty vector
(pL4440) as control. After 5–6 days, when the L1 animals had fully
developed, laid progeny, and the oldest progeny were L4 stage, the
entire population of animals in each well was washed off with
water and transferred immediately to empty 12-well plates and
were tested for swimming-induced paralysis (SWIP) suppression
after 10 min. The wells in which .40% of tested animals showed
sustained swimming after 10 min were considered to be positive
‘‘hits’’ and were retested in triplicate for SWIP using the exact
same conditions as in the original screen. Only dsRNAs that
retested at least twice were selected for further study.
Behavioral assays
SWIP assays on individual strains were performed by picking 10
L4 animals away from food and then placing them in a 50 mL
water droplet on a Menzel Glaser 10-well diagnostic slide (model
X1XER308B#) and scoring for swimming after 10 min. Swim-
ming was defined as the presence of free alternating body bends
characteristic of C. elegans swimming behavior [72]. This assay was
repeated for a total of 50 animals per strain.
DA dose-response assays were performed as described previ-
ously [25]. Briefly ,25 young adults for each strain were
incubated undisturbed for 20 min on plates containing the
indicated concentration of DA, and then scored for paralysis.
Animals were considered paralyzed if they did not exhibit at least
one spontaneous body bend in a 20 sec observation period. Assays
were repeated in triplicate for a total of at least 75 animals per
strain.
Basal slowing assays were done as previously described [25].
Briefly, the locomotion rates of staged young adult animals were
quantified by counting the number of body bends completed in
five consecutive 20 sec intervals in the presence or absence of
HB101 bacteria. Plates with bacteria were prepared by spreading
100 ml of HB101 bacteria (A600=0.70–0.75) across each plate and
incubation overnight at 37uC. Data were collected for six animals
per strain per condition (food, no food) for a total of 30
measurements per condition. Percent slowing was calculated by
dividing the difference between locomotion rates on and off food
by the locomotion rate off food.
Transgenic animals
To examine the expression pattern of RSBP-1 we constructed a
transgene with the promoter of rsbp-1 (3,260 nucleotide basepairs
upstream of the start codon) fused to the coding sequence for GFP
(pCL114) and injected it, together with a lin-15-rescuing plasmid
as marker (pL15EK, both plasmids injected at 50 ng/ml), into
MT8189 (lin-15(n765)) animals to generate the strain XP369.
Transgenic animals were identified by the absence of the multiple
vulva phenotype typical of lin-15(n765) mutants and by green
fluorescence. To generate double transgenic lines containing both
rsbp-1p::GFP and dop-3p::RFP transgenes, we crossed XP369
animals and LX811 (lin-15B(n745) X; vsIs33,[ dop-3p::RFP]
animals. For double transgenic lines between rsbp-1p::GFP and
unc-47p::mCherry, we crossed XP369 and XP300 (unc-47p::mcherry
transgenic line, generous gift of M. Francis). For generating double
transgenic lines between dop-1p::GFP and rsbp-1p::mCherry, a rsbp-
1p::mCherry construct (pCL133, promoter identical to pCL114)
(at 50 ng/ml) was injected into dop-1p::GFP animals (LX798) and
the double transgenic animals were identified by their green and
red fluorescence.
Cell-specific rescue
For generating rescue transgenic lines each rescue plasmid [rsbp-
1p:: rsbp-1 (pCL127, containing 3,260 bp of rsbp-1 promoter region
fused to cDNA encoding RSBP-1), unc-119p::rsbp-1 (pCL129,
containing 2,181 bp of unc-119 promoter region fused to cDNA
encoding RSBP-1), unc-17p::rsbp-1 (pCL130 containing 3,249 bp
of unc-17 promoter region fused to cDNA encoding RSBP-1), unc-
47p::rsbp-1 (pCL131, containing 257 bp of unc-47 promoter region
fused to cDNA encoding RSBP-1) and myo-3p::rsbp-1 (pCL132,
containing 2,379 bp except 7 bp immediately upstream of the
start codon of myo-3 promoter region fused to cDNA encoding
RSBP-1)], was injected at 50 ng/ml along with the co-injection
marker, myo-2p::GFP (pJK4) at 30 ng/ml into rsbp-1 mutant
animals (LX1270). For control lines, empty vectors containing
only the respective promoters were injected at 50 ng/ml along with
myo-2p::GFP at 30 ng/ml. For both rescue and control plasmids, 2–
3 independent lines were generated and tested side by side for the
rescue of the dopamine sensitivity of rsbp-1 mutants. For each line
25 animals in triplicate were tested on exogenous dopamine for a
total of 75 animals per line.
Statistical analysis
Comparisons shown in Figures 1, 2B, 4, 5A, and 6 were done
using one-way ANOVA with Bonferroni post hoc test. In
Figures 2A and 5B we compared the curves of each mutant to
the wildtype or other appropriate control (see result section) using
Modulation of D1 Receptor Signaling in C. elegans
PLoS ONE | www.plosone.org 10 May 2012 | Volume 7 | Issue 5 | e37831a two-way ANOVA with repeated measures followed by a
Bonferroni multiple comparisons post hoc test.
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